MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells
- PMID: 25531331
- DOI: 10.1038/onc.2014.430
MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells
Erratum in
-
MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells.Oncogene. 2015 Jul 23;34(30):4018. doi: 10.1038/onc.2015.201. Oncogene. 2015. PMID: 26202215 No abstract available.
Abstract
miRNAs (microRNAs) are frequently and aberrantly expressed in many cancers. MiR-873 has been revealed to be downregulated in colorectal cancer and glioblastoma. However, its function remains unclear. Here we report that miR-873 is downregulated in breast tumor compared with normal tissue. Enforced expression of miR-873 decreases the transcriptional activity of ER (estrogen receptor)-α but not ERβ through the modulation of ERα phosphorylation in ER-positive breast cancer cells. We also found that miR-873 inhibits breast cancer cell proliferation and tumor growth in nude mice. Reporter gene assays revealed cyclin-dependent kinase 3 (CDK3) as a direct target of miR-873. CDK3 was shown to be overexpressed in breast cancer and phosphorylate ERα at Ser104/116 and Ser118. Furthermore, we found that Mir-873 inhibits ER activity and cell growth via targeting CDK3. Interestingly, miR-873 was observed to be downregulated in tamoxifen-resistant MCF-7/TamR cells, while CDK3 is overexpressed in these cells. More importantly, re-expression of miR-873 reversed tamoxifen resistance in MCF-7/TamR cells. Our data demonstrate that miR-873 is a novel tumor suppressor in ER-positive breast cancer and a potential therapeutic approach for treatment of tamoxifen-resistant breast cancer.
Similar articles
-
Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.PLoS One. 2019 May 23;14(5):e0217181. doi: 10.1371/journal.pone.0217181. eCollection 2019. PLoS One. 2019. PMID: 31120927 Free PMC article.
-
miR-125a-3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer.FASEB J. 2018 Feb;32(2):588-600. doi: 10.1096/fj.201700461RR. Epub 2018 Jan 4. FASEB J. 2018. PMID: 28939591
-
Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.Mol Cell Endocrinol. 2016 May 15;427:133-42. doi: 10.1016/j.mce.2016.03.012. Epub 2016 Mar 12. Mol Cell Endocrinol. 2016. PMID: 26980484
-
Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3.Oncotarget. 2016 Sep 6;7(36):58595-58605. doi: 10.18632/oncotarget.11193. Oncotarget. 2016. PMID: 27517632 Free PMC article. Review.
-
Clinical significance of estrogen receptor phosphorylation.Endocr Relat Cancer. 2011 Jan 19;18(1):R1-14. doi: 10.1677/ERC-10-0070. Print 2011 Feb. Endocr Relat Cancer. 2011. PMID: 21149515 Review.
Cited by
-
Norcantharidin in cancer therapy - a new approach to overcoming therapeutic resistance: A review.Medicine (Baltimore). 2024 Mar 1;103(9):e37394. doi: 10.1097/MD.0000000000037394. Medicine (Baltimore). 2024. PMID: 38428865 Free PMC article. Review.
-
Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer.J Oncol. 2022 Jan 11;2022:4889807. doi: 10.1155/2022/4889807. eCollection 2022. J Oncol. 2022. PMID: 35087589 Free PMC article. Review.
-
LncRNA ATXN8OS enhances tamoxifen resistance in breast cancer.Open Med (Wars). 2020 Dec 15;16(1):68-80. doi: 10.1515/med-2021-0012. eCollection 2021. Open Med (Wars). 2020. PMID: 33385064 Free PMC article.
-
Development and validation of a novel circular RNA as an independent prognostic factor in acute myeloid leukemia.BMC Med. 2021 Feb 1;19(1):28. doi: 10.1186/s12916-020-01898-y. BMC Med. 2021. PMID: 33517886 Free PMC article.
-
Functional miRNAs in breast cancer drug resistance.Onco Targets Ther. 2018 Mar 19;11:1529-1541. doi: 10.2147/OTT.S152462. eCollection 2018. Onco Targets Ther. 2018. PMID: 29593419 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous